Abstract
8554Background: Pemtrexed/cisplatin (PCisp) remains the standard frontline treatment for advanced-stage MPM. However, a majority of patients are older and too fragile to tolerate PCisp. Because of better tolerance, pemetrexed/carboplatin (PCarb) is being used. To compare efficacy and safety of PCarb versus PCisp in MPM, we conducted a comprehensive systematic review and meta-analysis. Methods: Medline, EMBASE, and Cochrane databases were searched, in addition to proceedings from major meetings. Comparative and single-arm studies were included. Primary endpoints were overall survival (OS), progression-free survival (PFS), objective response rate (ORR) & disease control rate (DCR). Secondary safety endpoints were analyzed. Study heterogeneity, publication bias, and sensitivity analysis were assessed. Risk ratio (RR), HR, and 95% CI were calculated using random-effects models. Results: Initial search identified 972 studies; 23 [11 prospective (5 randomized), 12 retrospective] with a total of 3170 patients (8...